ERBB2 and breast cancer: Immunohistochemical analysis of 120 paraffin-embedded BC samples revealed that HER2<sup>+</sup> tumours exhibited significantly higher receptor activator of nuclear factor (NF)-κB (RANK) expression compared to HER2-negative (HER2<sup>-</sup>) tumours.